ENSYME IMMUNOASSAY FOR 8-ISO-2,3-DINOR PROSTAGLADIN F1
Award amount
$99,871Program and phase
SBIR · Phase IAward year
1998Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- Not reported
- Recipient company
- CAYMAN CHEMICAL COMPANY, INCORPORATED
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- T1ZHJRGR7TF4
- Solicitation number
- Not reported
- Topic code
- NIEHS
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Epigenetic Compounds Stimulating Dental Bone Repair
- Novel Small Molecule for Improved Dental Implant Osseointegration
- Hyperphosphorylated tau aggregation kit to identify tauopathy risk factor
- Development of a novel small molecule-based approach for accelerated fracture repair in the aging skeleton
- Hyperphosphorylated tau aggregation kit to identify tauopathy risk factor
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Bioinspired Green Glycolipids as Fugitive Dust Mitigation Agents
- Supercritical Fluid Cartridges for Calibration of Air Pollution Sensors
- Weight Loss and Endocrine Disrupting Chemicals (EDCs): Lifestyle interventions to lose weight and reduce EDC exposure in individuals with overweight/obesity
- High-Resolution Ground-Level AQ Monitoring System Using Hyper-local Low-cost Sensor Nodes and AI Forecasting
- Bringing PFAS Monitoring Home: An Integrated Magnetic Nanoparticle and Lateral Flow Assay System
Research funding history
6 SBIR/STTR records share this UEI (1998–2025). Reported award amounts total $5,323,029. Reported amounts are not federal obligations.
Phases: Phase I, Phase II – Direct to Phase II, Phase II
Agencies: Department of Health and Human Services